Literature DB >> 34236996

Finding the Optimal Partner to Pair with Bispecific Antibody Therapy for Multiple Myeloma.

Cedric Louvet1, Omar Nadeem1, Eric L Smith2.   

Abstract

BCMA/CD3ε-targeted bispecific antibody (BsAb) therapy represents a promising T cell-redirecting immunotherapy to treat relapsed and refractory multiple myeloma. However, rational combination strategies will most likely be key to achieve a long-lasting immune response. In this issue, Meermeier and colleagues investigate BsAb therapy in a syngeneic multiple myeloma model and elucidate that partnering with cyclophosphamide is associated with tempered activation, mitigated exhaustion of T cells, and is superior to pomalidomide or bortezomib in enhancing durable anti-multiple myeloma efficacy.See related article by Meermeier et al., p. 354. ©2021 American Association for Cancer Research.

Year:  2021        PMID： 34236996      PMCID： PMC8265983          DOI： 10.1158/2643-3230.BCD-21-0073

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  9 in total

1.  GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.

Authors:  Eric L Smith; Kim Harrington; Mette Staehr; Reed Masakayan; Jon Jones; Thomas J Long; Khong Y Ng; Majid Ghoddusi; Terence J Purdon; Xiuyan Wang; Trevor Do; Minh Thu Pham; Jessica M Brown; Carlos Fernandez De Larrea; Eric Olson; Elizabeth Peguero; Pei Wang; Hong Liu; Yiyang Xu; Sarah C Garrett-Thomson; Steven C Almo; Hans-Guido Wendel; Isabelle Riviere; Cheng Liu; Blythe Sather; Renier J Brentjens
Journal:  Sci Transl Med       Date:  2019-03-27       Impact factor: 17.956

2.  Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.

Authors:  Renier J Brentjens; Eric L Smith; Carlos Fernández de Larrea; Mette Staehr; Andrea V Lopez; Khong Y Ng; Yunxin Chen; William D Godfrey; Terence J Purdon; Vladimir Ponomarev; Hans-Guido Wendel
Journal:  Blood Cancer Discov       Date:  2020-09

3.  Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

Authors:  Nikhil C Munshi; Larry D Anderson; Nina Shah; Deepu Madduri; Jesús Berdeja; Sagar Lonial; Noopur Raje; Yi Lin; David Siegel; Albert Oriol; Philippe Moreau; Ibrahim Yakoub-Agha; Michel Delforge; Michele Cavo; Hermann Einsele; Hartmut Goldschmidt; Katja Weisel; Alessandro Rambaldi; Donna Reece; Fabio Petrocca; Monica Massaro; Jamie N Connarn; Shari Kaiser; Payal Patel; Liping Huang; Timothy B Campbell; Kristen Hege; Jesús San-Miguel
Journal:  N Engl J Med       Date:  2021-02-25       Impact factor: 91.245

4.  The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.

Authors:  Shih-Feng Cho; Liang Lin; Lijie Xing; Yuyin Li; Kenneth Wen; Tengteng Yu; Phillip A Hsieh; Nikhil Munshi; Joachim Wahl; Katja Matthes; Matthias Friedrich; Tara Arvedson; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Blood Adv       Date:  2020-09-08

5.  γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.

Authors:  Margot J Pont; Tyler Hill; Gabriel O Cole; Joe J Abbott; Jessica Kelliher; Alexander I Salter; Michael Hudecek; Melissa L Comstock; Anusha Rajan; Bharvin K R Patel; Jenna M Voutsinas; Qian Wu; Lingfeng Liu; Andrew J Cowan; Brent L Wood; Damian J Green; Stanley R Riddell
Journal:  Blood       Date:  2019-11-07       Impact factor: 22.113

6.  Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.

Authors:  Shivani Srivastava; Scott N Furlan; Carla A Jaeger-Ruckstuhl; Megha Sarvothama; Carolina Berger; Kimberly S Smythe; Sarah M Garrison; Jennifer M Specht; Sylvia M Lee; Robert A Amezquita; Valentin Voillet; Vishaka Muhunthan; Sushma Yechan-Gunja; Smitha P S Pillai; Christoph Rader; A McGarry Houghton; Robert H Pierce; Raphael Gottardo; David G Maloney; Stanley R Riddell
Journal:  Cancer Cell       Date:  2020-12-24       Impact factor: 31.743

7.  Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice.

Authors:  Emma C Fink; Marie McConkey; Dylan N Adams; Saurav D Haldar; James A Kennedy; Andrew A Guirguis; Namrata D Udeshi; D R Mani; Michelle Chen; Brian Liddicoat; Tanya Svinkina; Andrew T Nguyen; Steven A Carr; Benjamin L Ebert
Journal:  Blood       Date:  2018-07-31       Impact factor: 25.476

8.  Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.

Authors:  J Duell; M Dittrich; T Bedke; T Mueller; F Eisele; A Rosenwald; L Rasche; E Hartmann; T Dandekar; H Einsele; M S Topp
Journal:  Leukemia       Date:  2017-01-25       Impact factor: 11.528

Review 9.  Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma.

Authors:  Dawn Swan; Mark Gurney; Janusz Krawczyk; Aideen E Ryan; Michael O'Dwyer
Journal:  Hemasphere       Date:  2020-04-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.